ERBB2 and breast cancer: No significant difference in OS was found between BRCA-carriers and noncarriers among patients with HR-negative BC (adjusted HR: 0.81 [95% confidence interval [CI]: 0.43–1.53], p = 0.51) or considering HER2 status (adjusted HR 0.95 [95% CI: 0.43–2.07], p = 0.89).